Moxifloxacin in the Initial Therapy of Tuberculosis: A Randomized, Phase 2 Trial

BACKGROUND: New therapies are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new agent that may have additive activity to existing antituberculosis agents. We conducted a Phase 2 clinical trial to determin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Conde, Marcus B., Efron, Anne, Loredo, Carla, Muzy De Souza, Gilvan R., Graça, Nadja P., Cezar, Michelle C., Ram, Malathi, Chaudhary, Mohammad A., Bishai, William R., Kritski, Afranio L., Chaisson, Richard E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2009
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2866651/
https://ncbi.nlm.nih.gov/pubmed/19345831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(09)60333-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi